Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immunome ( (IMNM) ) has issued an update.
On December 15, 2025, Immunome announced positive topline results from its Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors. The trial demonstrated significant improvements in progression-free survival and objective response rate compared to placebo, with varegacestat showing an 84% reduction in the risk of disease progression or death. The company plans to submit a New Drug Application to the FDA in Q2 2026, positioning varegacestat as a potential new standard of care for desmoid tumors.
The most recent analyst rating on (IMNM) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Immunome stock, see the IMNM Stock Forecast page.
Spark’s Take on IMNM Stock
According to Spark, TipRanks’ AI Analyst, IMNM is a Neutral.
Immunome’s stock score is primarily influenced by its challenging financial performance, with significant losses impacting profitability. However, the technical analysis indicates strong bullish momentum, which is a positive factor. The valuation is negatively impacted by the negative P/E ratio and lack of dividend yield.
To see Spark’s full report on IMNM stock, click here.
More about Immunome
Immunome, Inc. is a clinical-stage biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies. The company is advancing a portfolio of therapeutics, including varegacestat, a gamma secretase inhibitor, and other innovative treatments targeting solid tumors.
Average Trading Volume: 1,447,645
Technical Sentiment Signal: Buy
Current Market Cap: $1.79B
See more data about IMNM stock on TipRanks’ Stock Analysis page.